The Clinical Efficacy of DFPP in Patients With AAGN

A Prospective, Controlled Study of Double Filtration Plasmapheresis (DFPP) in Patients With Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis (AAGN)

The clinical efficacy of double filtration plasmapheresis(DFPP) in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).

This is a single center, prospective, randomized,controlled study to compare the clinical efficacy of double filtration plasmapheresis (DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy versus IV-CTX pulse therapy in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).

Inclusion Criteria:

• a diagnosis of ANCA associated vasculitis(AAV), using criteria adapted from the disease definitions of the Chapel Hill consensus conference
• serum positive ANCA and the ANCA level ≥100 relative unit/ml
• with renal involvement and serum creatinine≥3 mg/dl
• written informed consent had been provided.

Exclusion Criteria:

• other secondary vasculitis
• anti-glomerular basement membrane(GBM) positive
• severe infection; hepatitis B antigenemia, anti- hepatitis C virus
• immunodeficiency; or immunoglobulin G(IgG)<2g/l
• life threatening
• renal biopsy show globally sclerotic glomeruli>60% and normal glomeruli<10%
• need renal replacement therapy for more than 4w
• received large dose of methylprednisolone(MP),CTX,mycophenolate mofetil(MMF), plasmapheresis or intravenous immunoglobulin(IVIg) therapy.